Compass Therapeutics, Inc. (CMPX)

Over the past six months, Compass Therapeutics, Inc.'s stock price saw a significant increase of 227.22%. Key events include the Third Quarter 2025 Financial Results and Corporate Update, where the company reported a Q3 2025 net loss of $14.3 million due to heightened R&D investments. The company presented preclinical data on CTX-10726 at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting. Compass participated in several investor events, and announced inducement grants under Nasdaq Listing Rule 5635(c)(4) in January 2026. William Blair initiated coverage with an outperform recommendation, and other analysts reiterated Buy ratings.

As a clinical-stage biopharmaceutical company, Compass Therapeutics, Inc. does not have traditional demand seasonality for its products and services. Its revenue generation is primarily tied to research and development milestones, partnerships, and potential future product approvals. However, historical stock price data suggests some seasonality in its stock performance, with buying CMPX stock in June historically showing the highest probability of a positive return.

Compass Therapeutics, Inc. (CMPX) is a clinical-stage biopharmaceutical company focused on oncology, operating within the Healthcare sector. The company develops antibody therapeutics to engage the immune system for treating solid tumors and hematological malignancies, leveraging its proprietary antibody discovery engine to identify optimal drug combinations. Its pipeline includes product candidates like CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371, targeting critical biological pathways for anti-tumor response.

Compass Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States, with primary operations centered around research, development, and clinical trials. Information regarding a broader international geographic footprint for commercial operations or product sales is not explicitly available, consistent with its current development stage.

Compass Therapeutics, Inc. has generally maintained a positive reputation among financial analysts, with a consensus rating of Moderate Buy. However, its reputation is subject to the inherent risks of drug development, with past challenges such as the failure of dilpacimab raising concerns. Despite these challenges, the company has demonstrated promising data in colorectal cancer with other candidates and observed progress with CTX-8371, contributing to a positive outlook on its financial health and future growth.

Approximately 84.88% to 84.93% of Compass Therapeutics, Inc.'s stock is held by institutional shareholders, insiders hold between 21.48% and 29.80%, and the general public holds about a 19% stake. Major institutional owners include Tang Capital Management Llc, Orbimed Advisors Llc, and Suvretta Capital Management, Llc. Orbimed Advisors LLC is the largest individual shareholder, owning 15.22 million shares, and the company's CEO, Thomas Schuetz, directly holds 4.1% of the total shares outstanding.